Researchers demonstrated the role of an inflammatory subset of CD4 memory cells in patients with juvenile idiopathic arthritis who are in remission and will relapse on anti-TNF withdrawal.
Researchers evaluated Canadian claims level data to assess the utilization of methotrexate and prednisone in patients with JIA who initiated etanercept therapy.
Researchers assessed the efficacy and safety of leflunomide, as an alternative to methotrexate, in patients with juvenile idiopathic arthritis.
The study assessed the implications of genetic advances in juvenile idiopathic arthritis; the results of the research may be useful in the treatment of arthritis in children.
The study investigated the outcomes of pregnancies involving patients with JIA exposed to DMARDs.
Multiple stakeholders were brought together to discuss the challenges surrounding trials, and the testing and authorization of new medicines for juvenile idiopathic arthritis.
This study evaluated the frequency of achieving inactive disease in children with JIA treated solely with methotrexate and identified a model for patients with a lesser likelihood of reaching inactive disease with methotrexate.
The study aimed to describe clinical characteristics, risk factors, histopathologic and immunologic features of systemic juvenile idiopathic arthritis-associated lung disease (SJIA-LD).
The study evaluated IL-18 levels in systemic juvenile idiopathic arthritis by assessing disease activity, history of macrophage activation syndrome, and other disease biomarkers.
Investigators assessed the real-world efficacy of simple strategies to treat juvenile idiopathic arthritis as current guidelines recommend.
